This data allows PlexusDx providers to recommend semaglutide, tirzepatide, or GLP-Squared (dual-compound) with confidence based on your genetics, not guesswork
Compared with placebo, the smallest percentage body-weight loss was observed in individuals with type 2 diabetes, with an estimated treatment difference of 6.2% after 68 weeks of treatment [35], whereas an additional body-weight loss of 10.312.5% after 68 weeks of treatment (without prior run-in with semaglutide) was observed in individuals without diabetes in trials aiming to directly compare semaglutide with placebo [26, 36, 38, 39] (Fig
You develop signs of hypoglycaemia : Whilst both Rybelsus and Januvia have low intrinsic hypoglycaemia risk, combining them with insulin or sulphonylureas increases this possibility
Unfortunately, more than 50 percent of people who start GLP-1 drugs quit after one year most likely due to its side effects (1)
Fortunately, it is also rare, and the vast majority of children affected by it survive